Last reviewed · How we verify
Botulinum neurotoxin (BTX)
Botulinum neurotoxin blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Botulinum neurotoxin blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | Botulinum neurotoxin (BTX) |
|---|---|
| Also known as | Botox |
| Sponsor | The University of Texas Health Science Center, Houston |
| Drug class | Neurotoxin; acetylcholine release inhibitor |
| Target | SNARE proteins (SNAP-25, VAMP, syntaxin) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Aesthetics; Pain Management |
| Phase | FDA-approved |
Mechanism of action
BTX is a bacterial toxin that irreversibly cleaves proteins (SNAP-25, VAMP, or syntaxin) required for acetylcholine vesicle fusion and release at the presynaptic terminal. This results in temporary denervation and muscle weakness lasting 3–4 months, after which new neuromuscular junctions form and function is restored. The effect is localized to the injection site.
Approved indications
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
- Chronic migraine
- Spasticity
- Hyperhidrosis
- Cosmetic wrinkle reduction
Common side effects
- Injection site pain or bruising
- Headache
- Muscle weakness or paralysis (off-target)
- Ptosis (eyelid drooping)
- Antibody formation (neutralizing antibodies)
Key clinical trials
- Botulinum Toxin for the Treatment of Involuntary Movement Disorders
- Botulinum Toxin A vs Strabismus Surgery for Esotropia (PHASE3)
- Botulinum Toxin A Before Hemorrhoidectomy to Prevent Postoperative Pain (PHASE2)
- Botulinum Toxin Injection in Reducing Scar Following Cheilorrhaphy. (NA)
- Botulinum Toxin Versus Platelet Rich Fibrin for TMJ Internal Derangement (NA)
- Comparative Study Between Botulinum Toxin-A Injection and Shock Waves on Hypertrophic Scars in Hand-burned Children (NA)
- The Effectiveness of Guided Botulinum Toxin "A" Injection to the Masticatory Muscles in the Management of Condylar and Subcondylar Fractures (NA)
- Management of Bruxism in Patients With Implant Overdenture (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: